Cost-effectiveness analysis of first-line gifitinib plus pemetrexed-platinum-based chemotherapy versus gifitinib monotherapy in EGFR-mutated NSCLC patients with brain metastases

ABSTRACT:

SUBMITTER: Zhao Z 

PROVIDER: S-EPMC12382008 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature